Founded in 1986 and based in New York, Swiss Helvetia Fund focuses on investing in Swiss companies, despite being located in the United States. The fund typically invests in startups that are 6-10 years old and operates in thriving sectors such as mineral and biotechnology. Some of its notable portfolio startups include Kuros Biosciences and Synosia Therapeutics. The fund often participates in investment rounds with 5 other investors and has received funding from Versant Ventures, VI Partners AG, and VINCI CAPITAL. In terms of performance, Swiss Helvetia Fund has a higher exit rate compared to other organizations and experienced the most exits in 2016. The fund is involved in less than 2 deals per year on average and has a higher number of lead investments compared to other companies. Typical investments range from $10-50 million.